Silence Therapeutics said this week that it has been issued a Japanese patent covering its core RNAi technology.

The patent, No. 4,705,370, is entitled “Further Novel Forms of Interfering RNA Molecules,” and claims siRNAs containing proprietary 2’-O-methyl structures.

“The ability to expand our strong RNAi patent portfolio into a large pharmaceutical market such as Japan represents … [a] success in our proactive ongoing intellectual property strategy,” Silence CEO Philips Haworth said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.